Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Tuesday, March 17, 2026 at 8:30 a.m. ET (12:30 p.m. GMT). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

About Alkermes plc
Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Alkermes’ pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260310615520/en/

Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402

Tags

More Like This

Alkermes to Present at the TD Cowen 46th Annual Health Care Conference

Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Alkermes to Participate in Upcoming Investor Conferences

Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Alkermes to Participate in Two Upcoming Investor Conferences

Alkermes to Participate in Two Upcoming Investor Conferences

Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference

Alkermes to Participate in Two Upcoming Investor Conferences